Helomics and Viome to study gut microbiome link to ovarian cancer

Helomics partnered with artificial intelligence company Viome to study the link between the gut microbiome and ovarian cancer to develop approaches to help doctors personalize treatment.

The collaboration will utilize Helomics’ drug response and genomic profiling of patients’ tumors, coupled with its AI-powered bioinformatics platform, D-CHIP, combined with the microbiome analysis platform and AI technology of Viome Inc. (Los Alamos, N.M.)...